What Happened
South Africa's pharmacy council and medicines regulator are jointly rewriting the country's compounding rules, in response to a wave of custom-made GLP-1 weight-loss products that regulators say has grown far beyond what the law was designed to permit.
The South African Pharmacy Council and the medicines regulatory authority are updating minimum standards and compounding guidelines, with the council expected to review the revised standards in February and publication targeted for March.
"What we are seeing in the market, and which we are against, is when pharmacies become small-scale manufacturers," said the council's registrar and CEO, Vincent Tlala — describing preparations made in anticipation of demand rather than for named individual patients. The regulator's market-control lead, Daphney Fafudi, described "a scourge of compounded products, especially in the area of weight-loss," attributing the boom to demand for cheaper versions of brand-name GLP-1 medicines.
Who Is Affected
- Compounding pharmacies, whose legal operating space will be redefined by the February review
- Patients and consumers buying compounded GLP-1s, who may not know whether their product was prepared for them or batch-produced for anonymous demand
- Originator manufacturers, which have litigated against compounders and pushed for clearer rules
- Researchers sourcing GLP-1 materials, since compounding gray zones also feed the research-chemical supply chain
Timeline
- 2023-2025: Global GLP-1 shortages trigger a boom in compounded semaglutide across multiple jurisdictions, including South Africa
- 2026: A Johannesburg compounder's interim ban on selling compounded semaglutide is upheld after leave to appeal is refused
- October 2026: Both regulators confirm the rules are being rewritten; industry is told to expect clarified standards
- February 2027: Council review of the revised minimum standards
- March 2027: Targeted publication of the new standards and guidelines
What This Means for Researchers
The rewrite formalizes a distinction the gray market has spent years blurring: a medicine prepared for a named patient is a pharmacy service; a batch of vials produced for anticipated demand is manufacturing, with all the facility, sterility and accountability requirements that entails.
Regulators themselves named interpretation disputes as the reason for the update — existing provisions technically govern compounding, but divergent readings produced the litigation and gray-area supply the new standards are meant to close. For researchers, the practical consequence is a cleaner definition of who may lawfully produce GLP-1 material, and therefore which suppliers operate under any form of oversight. A seller outside that definition is not a pharmacy in any sense that matters analytically.
How to Verify Your Peptides
- The semaglutide purity testing guide explains how analytical testing confirms label claims
- How testing works walks through the full verification workflow
- Batch-made products of any origin can be checked through independent third-party labs
Safe Alternatives
- Background on the two most-copied molecules: semaglutide and tirzepatide
- Before any purchase, review the peptides directory and vetted vendor listings
Sources
Regulatory announcements concerning pharmacy compounding standards; industry statements at a pharmaceutical sector briefing.